<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01463059</url>
  </required_header>
  <id_info>
    <org_study_id>RA0083</org_study_id>
    <nct_id>NCT01463059</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Asian Subjects With Active Rheumatoid Arthritis Having Previously Failed TNF Blocker Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Japan Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy and safety of CDP6038
      administered subcutaneous (sc) at various doses compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Disease Activity Score 28-joint count (C-reactive protein) (DAS28[CRP]) at Week 12</measure>
    <time_frame>From Week 0 (Baseline) to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of responders in American College of Rheumatology 20% Response Criteria (ACR20) at Week 12</measure>
    <time_frame>From Week 0 (Baseline) to Week 12</time_frame>
    <description>Number of subjects who achieve ACR 20 will be calculated at week 12. The calculation is based on the improvement from the baseline in the number of tender joints and in the number of swollen joints each; and the improvement based on assessments from the patient and the physician drawn according to defined standards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responders in American College of Rheumatology 50% Response Criteria (ACR50) at Week 12</measure>
    <time_frame>From Week 0 (Baseline) to Week 12</time_frame>
    <description>Number of subjects who achieve ACR 50 will be calculated at week 12. The calculation is based on the improvement from the baseline in the number of tender joints and in the number of swollen joints each; and the improvement based on assessments from the patient and the physician drawn according to defined standards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responders in American College of Rheumatology 70% Response Criteria (ACR70) at Week 12</measure>
    <time_frame>From Week 0 (Baseline) to Week 12</time_frame>
    <description>Number of subjects who achieve ACR 70 will be calculated at week 12. The calculations is based on the improvement from the baseline in the number of tender joints and in the number of swollen joints each; and the improvement based on assessments from the patient and the physician drawn according to defined standards.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo every 2 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injections administered at week 0, 2, 4, 6, 8 and 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olokizumab 60 mg every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olokizumab 60 mg injections administered at week 0, 2, 4, 6, 8 and 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olokizumab 60 mg every 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olokizumab 60 mg injection administered at week 0, 4, and 8 and Placebo injection administered at week 2, 6, and 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olokizumab 120 mg every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olokizumab 120 mg injections administered at week 0, 2, 4, 6, 8 and 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olokizumab 120 mg every 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olokizumab 120 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olokizumab 240 mg very 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olokizumab 240 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution for injection, administered as subcutaneous injections</description>
    <arm_group_label>Placebo every 2 weeks</arm_group_label>
    <arm_group_label>Olokizumab 60 mg every 4 weeks</arm_group_label>
    <arm_group_label>Olokizumab 120 mg every 4 weeks</arm_group_label>
    <arm_group_label>Olokizumab 240 mg very 4 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Olokizumab 60 mg</intervention_name>
    <description>Olokizumab 60 mg solution for injection, administered as subcutaneous injections</description>
    <arm_group_label>Olokizumab 60 mg every 2 weeks</arm_group_label>
    <arm_group_label>Olokizumab 60 mg every 4 weeks</arm_group_label>
    <other_name>CDP6038</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Olokizumab 120 mg</intervention_name>
    <description>Olokizumab 120 mg solution for injection, administered as subcutaneous injections</description>
    <arm_group_label>Olokizumab 120 mg every 2 weeks</arm_group_label>
    <arm_group_label>Olokizumab 120 mg every 4 weeks</arm_group_label>
    <other_name>CDP6038</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Olokizumab 240 mg</intervention_name>
    <description>Olokizumab 240 mg solution for injection, administered as subcutaneous injections</description>
    <arm_group_label>Olokizumab 240 mg very 4 weeks</arm_group_label>
    <other_name>CDP6038</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of adult-onset RA of at least 6 months' (24 weeks) duration as
             defined by the 1987 ACR classification criteria or a score of ≥6 as defined by the
             ACR/European League Against Rheumatism Classification and Diagnostic Criteria for RA

          -  Must have moderately to severely active RA disease as defined by ≥6 tender joints
             (68-joint count) at Screening and Baseline, ≥6 swollen joints (66-joint count) at
             Screening and Baseline, CRP ≥1.2 times the upper limit of normal (ULN) or ESR
             &gt;28mm/hour

          -  Must be on an MTX dose of 6 to 16mg/week in Japan or 7.5 to 20mg/week in Korea and
             Taiwan, which has been stable for at least 6 weeks prior to Screening with a stable
             route of administration

          -  Must have had intolerance or inadequate response to treatment with 1 or more
             TNF-blocker therapies within 2 years of Screening

          -  Female subjects must be either postmenopausal for at least 1 year, surgically
             incapable of childbearing, or effectively practicing 2 acceptable methods of
             contraception

        Exclusion Criteria:

          -  Have a diagnosis of any other inflammatory arthritis

          -  Female subjects who are breast-feeding, pregnant, or plan to become pregnant during
             the study or within 24 weeks

          -  Disease modifying antirheumatic drug (DMARDs) other than methotrexate (MTX)

          -  Subjects with known concurrent acute or chronic viral hepatitis B or C infection

          -  Subject has known tuberculosis (TB) disease, high risk of acquiring TB infection, or
             latent TB infection

          -  Subjects with known history of or current clinically active infection

          -  Subjects at high risk of infection

          -  Subjects with known human immunodeficiency virus (HIV) or human T cell lymphotropic
             virus type 1 (HTLV 1) infection

          -  Have received vaccinations within 8 weeks prior to Screening or plan to receive
             vaccines during the study (with the exception of injectable influenza and pneumococcal
             vaccinations which are permitted)

          -  Concurrent malignancy or a history of malignancy (with the exception of successfully
             treated carcinoma of the cervix more than 5 years prior to Screening or no more than 2
             successfully treated basal cell carcinomas within 2 years prior to Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>102</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>114</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>115</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>113</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>120</name>
      <address>
        <city>Kakogawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>118</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>116</name>
      <address>
        <city>Kurume</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>121</name>
      <address>
        <city>Matsuyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>122</name>
      <address>
        <city>Matsuyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>107</name>
      <address>
        <city>Nagaoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>110</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>103</name>
      <address>
        <city>Narita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>119</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>112</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>100</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>117</name>
      <address>
        <city>Sasebo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>124</name>
      <address>
        <city>Tokorozawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>123</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>101</name>
      <address>
        <city>Tomakomai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>108</name>
      <address>
        <city>Tonami</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>111</name>
      <address>
        <city>Tsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>105</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>104</name>
      <address>
        <city>Yotukaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>200</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>201</name>
      <address>
        <city>Jung-gu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202</name>
      <address>
        <city>Seongdong-gu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>203</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>204</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>303</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>304</name>
      <address>
        <city>Dalin-Town</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>305</name>
      <address>
        <city>Hualien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>300</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>301</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>306</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>307</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>308</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>309</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>310</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2011</study_first_submitted>
  <study_first_submitted_qc>October 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2011</study_first_posted>
  <disposition_first_submitted>March 19, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>March 19, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 25, 2013</disposition_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <keyword>Interleukin-6</keyword>
  <keyword>Olokizumab</keyword>
  <keyword>CDP6038</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

